New research published in Current Oncology indicates a rise in late-stage prostate cancer cases in Canada may prompt a reevaluation of prostate cancer screening policies, particularly regarding the PSA test. The study highlights a 50% increase in metastatic cancer among men aged 50 to 74 since U.S. screening recommendations changed in 2010, while mortality rates have plateaued. However, some oncologists argue that improved treatment advances, rather than screening practices, account for these trends. The ongoing debate emphasizes the need for more accurate screening methods to differentiate between aggressive and indolent prostate cancers.
